对伴高凝状态的恶性肿瘤患者进行抗凝联合化疗的临床观察

目的：观察伴高凝状态的恶性肿瘤患者进行抗凝联合化疗的临床疗效。方法：对44例伴高凝状态恶性肿瘤患者进行抗凝加化疗,设为治疗组,给予一线标准方案化疗,同时给予低分子肝素钙6000U并伴随化疗,1次/d,皮下注射,阿司匹林100mgpo,1次/d,21～28d为1个周期,4个周期为1个疗程。对照组患者单独采用一线标准方案化疗。结果：治疗组和对照组有效率分别为22.7%和18.2%,两组比较,差异无统计学意义（P〉0.05）;两组中位生存期（MST）分别为30.2个月和29.2个月,两组比较,差异无统计学意义（P〉0.05）;治疗组和对照组KPS改善率分别为63.6%和36.4%,两组比较,差异有统计学意义（P〈0.05）。两组毒性反应基本相同。结论：伴高凝状态恶性肿瘤患者进行化疗时加抗凝治疗,效果较好,值得临床使用。

Clinical observation of anticoagulation combined chemotherapy in the treatment of malignant tumor patients with hypercoagulable state

Objective：To observe the clinical effect of anticoagulation combined chemotherapy in the treatment of malignant tumor patients with hypercoagulable state.Methods：44 malignant tumor patients with hypercoagulable state were enrolled into the study.They were accepted the treatment of the first standard chemotherapy and anticoagulation.The treat ment of anticoagulation included low-molecular-weight heparin calcium 6 000 U ih following the chemotherapy and asprin 100 mg po,qd,the treatment was repeated every 21-28 days.After 4 cycles of chemotherapy,the efficacy and toxicity were evaluated.The other 44 patients of the control group were only accepted the first standard chemotherapy.Results：The efficacious rates were 22.7%（treatment group） and 18.2%（control group）,there was no significant difference（P〈0.05）.The median survival time（MST） of the two groups were 30.2 months and 29.2 months,there was no significant difference（P 0.05）.The KPS improvement rate of the two groups were 63.6% and 36.4%,there was a significant difference（P〈0.05）.The toxicity of the two groups were almost close.Conclusion：It＇s benefit from anticoagulation combined chemotherapy for the malignant tumor patients with hypercoagulable state.It＇s worthy of promotion.